Clinical Trial Update: Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated active surveillance with or without apalutamide in men with low-risk prostate cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)

Snippet

Sponsor: Institut Paoli-Calmettes | Conditions: Low Risk Prostate Cancer | Phase 2 | Status: COMPLETED